Compare Immunovant Inc. Common Stock (IMVT) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs IONQ Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.27 (market cap $6.25B), while IONQ Inc trades at $39.54 (market cap $15.98B). The key difference: IONQ Inc is far larger — about 2.6× Immunovant Inc. Common Stock's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and IONQ Inc for 33 Days on average.
| IMVT | IONQ | |
|---|---|---|
Market Cap | $6.25B | $15.98B |
Volume | 1,755,411 | 22,848,240 |
Sector | Health | Technology |
52-Week High | $44.96 | $82.09 |
52-Week Low | $17.03 | $26.59 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $5.35B | $13.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IONQ trades at $41.34, down 4.5% today, with a mixed technical signal leaning bullish overall. The company reported revenue of $130.02M in 2025 but a net loss of $510.38M, reflecting high growth spending. Recent news highlights strong analyst backing, including Bank of America's Buy rating and $60 target, citing IonQ's trapped-ion quantum computing technology and partnerships.
Outlook: IonQ offers high growth potential in quantum computing, supported by bullish analyst targets averaging $62.75. Risks include persistent losses, cash burn, and intense competition. Investors should weigh the long-term disruptive potential against current profitability challenges and valuation premiums.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
